| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2011
Robyn Gearey |
What a Girl Wants: Diversification Meet Fool member Meredith Ohran talks about her investing portfolio.   |
The Motley Fool
June 14, 2011
Robyn Gearey |
What a Girl Wants: A Good Story This is part of a series of profiles highlighting women investors in the Motley Fool community. Today let's meet member Linda Queen. |
The Motley Fool
December 31, 2007
Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. |
The Motley Fool
June 17, 2011
Robyn Gearey |
What a Girl Wants: Gains Over Glamour As part of a series of profiles highlighting women investors in the Fool community, learn how one woman learned to be an investor. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk. |
The Motley Fool
May 2, 2011
Anupama Pattanaik |
J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion. |
The Motley Fool
August 24, 2010
Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock. |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years. |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
June 15, 2009
Todd Wenning |
Is Barron's Roundtable Wrong on Plum Creek? Barron's analyst thinks Plum Creek Timber REIT is over-priced. Do you agree? |
The Motley Fool
July 13, 2011 |
Roundtable: Can You Retire on These Stocks? Motley Fool writers weigh in with their opinions on the best and worst stocks for retirement portfolios. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
October 17, 2007
Brian Orelli |
J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
July 16, 2008
Brian Orelli |
J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification. |
BusinessWeek
January 30, 2006
Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it. |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks. |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors. |
The Motley Fool
November 29, 2011
John Grgurich |
3 Strong Yields From the Market's Biggest and Brightest Companies Earn sustainable dividends from companies you can count on to stick around: Intel... Microsoft... Johnson & Johnson... |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
J&J's New Baby As other divisions stumble, Johnson & Johnson's consumer products - bolstered by a $16.6 billion addition - provide a security blanket. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool
November 26, 2007
Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. |
BusinessWeek
April 17, 2006
Amy Barrett |
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock. |
BusinessWeek
December 22, 2003
Robert Barker |
A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths. |
The Motley Fool
December 22, 2009
Dave Mock |
A Big Upgrade for Plum Creek Timber This bullish call comes from more than just one analyst. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
October 26, 2011 |
A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward. |
The Motley Fool
September 7, 2011
Matt Koppenheffer |
3 Stocks to Play Stock-Market Defense Worried about the state of the economy? These three stocks can help defend your portfolio. |
The Motley Fool
September 17, 2010
Morgan Housel |
5 Companies That Doubled Earnings While Their Stocks Went Nowhere When being "paid for performance" loses its mind. |
The Motley Fool
November 29, 2007
Anders Bylund |
Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. |
The Motley Fool
April 13, 2006
Doug Short |
A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock. |
BusinessWeek
March 31, 2011
David Voreacos et al. |
Johnson & Johnson's Quality Catastrophe After 50-plus product recalls in 15 months, the $60 billion company is fighting to clear its once-trusted name. |
The Motley Fool
January 24, 2005
Dave Marino-Nachison |
J&J Snack Foods Won't Spoil Dinner The SuperPretzel and ICEE company looks like a solid performer that can grow. The stock seems fully valued at current prices and given the market's earnings estimates. |
The Motley Fool
June 27, 2008
Ryan Fuhrmann |
Recession-Proof Stocks: Johnson & Johnson This industry titan's stock is beaten down and should recover quite nicely when headwinds stop working against it and start to shift toward its back. |
The Motley Fool
February 24, 2004
Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
The Motley Fool
December 18, 2008
Selena Maranjian |
Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009. |
The Motley Fool
November 18, 2005
Stephen D. Simpson |
Diving Into the Dow: The Fourth Five The authors banter about the relative merits and investment opportunities of some the biggest companies in America: Honeywell International... Intel... IBM... Johnson & Johnson... JPMorgan Chase... |
The Motley Fool
November 15, 2005
Stephen D. Simpson |
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note. |
The Motley Fool
August 29, 2008
Richards et al. |
Fool Blog: Stocks We'd Recommend to Our Grandmas In lieu of this crazy market, analysts suggest stocks they would recommend for their own grandmothers? |
BusinessWeek
October 10, 2005 |
J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows. |
The Motley Fool
June 15, 2006
Selena Maranjian |
My Dividends Are Bigger Than Yours Your yield may be 2% when mine is a whopping 13%. Here's the secret. |
BusinessWeek
March 31, 2011 |
Johnson & Johnson's Recall Rap Sheet Fifteen months of recalls of everything from artificial hips to Tylenol. |
The Motley Fool
August 23, 2010
Andy Cross |
Today's Buy Opportunity: Seaspan There's a lot to like with Seaspan, but it certainly faces choppy seas that could rock the boat a bit. |
The Motley Fool
January 12, 2006
Stephen D. Simpson |
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note. |
